Summary

Japan Pharmacovigilance Market Research Report: Size, Share, Trend Analysis By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting), and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035

Market Summary:
As per Market Research Future analysis, the Japan pharmacovigilance market Size was estimated at 235.6 USD Million in 2024. The Japan pharmacovigilance market is projected to grow from 255.91 USD Million in 2025 to 585.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 8.6% during the forecast period 2025 - 2035

Market Drivers:
The pharmacovigilance market in Japan is experiencing heightened regulatory scrutiny, which is driving the demand for robust safety monitoring systems. Regulatory bodies, such as the Pharmaceuticals and Medical Devices Agency (PMDA), are enforcing stricter guidelines for drug safety reporting. This has led to an increased need for companies to invest in comprehensive pharmacovigilance systems to ensure compliance. As a result, the market is projected to grow at a CAGR of approximately 8% over the next few years. Companies are now prioritizing the implementation of advanced reporting tools and data analytics to meet these regulatory requirements, thereby enhancing the overall safety profile of pharmaceuticals in the market. The rapid expansion of biopharmaceuticals is significantly influencing the pharmacovigilance market in Japan. As the biopharmaceutical sector continues to grow, the complexity of monitoring these products increases. Biologics often have unique safety profiles that require specialized pharmacovigilance strategies. Consequently, pharmaceutical companies are investing in tailored monitoring systems to address the specific challenges associated with biopharmaceuticals.

Market Segment Analysis:
In the Japan pharmacovigilance market, the service type segment displays a diverse distribution among its key components. Adverse Event Reporting is currently the largest segment, capturing the most significant share of the market due to its critical importance in ensuring drug safety. Other services like Risk Assessment and Data Mining also hold notable positions; however, they do not surpass the dominance of Adverse Event Reporting. Furthermore, Pharmacovigilance Consulting is emerging as the fastest-growing segment, driven by increasing regulatory requirements and the need for expert guidance in drug safety management. Growth trends indicate that the Japan pharmacovigilance market is evolving, with a strong inclination towards technology-driven solutions and real-time data analytics. This shift is particularly noticeable in Data Mining, which is becoming essential for detecting adverse drug reactions efficiently.

Regional Analysis:
The pharmacovigilance market in Japan is currently experiencing notable growth, driven by increasing regulatory requirements and a heightened focus on patient safety. The Japanese government has implemented stringent regulations to ensure the safety and efficacy of pharmaceuticals, which has led to a greater demand for robust pharmacovigilance systems. This trend is further supported by the rising number of clinical trials and the introduction of innovative therapies, necessitating comprehensive monitoring of adverse drug reactions. As a result, pharmaceutical companies are investing significantly in pharmacovigilance capabilities to comply with these regulations and enhance their market position. Moreover, advancements in technology are transforming the pharmacovigilance landscape in Japan.

Major Players:
The following companies are key participants in the Japan Pharmacovigilance Market, playing a crucial role in market development through technological innovation, strategic partnerships, and competitive product offerings.

ページTOPに戻る

Table of Contents

TABLE OF CONTENT
1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
EXECUTIVE SUMMARY
Market Overview
Key Findings
Market Segmentation
Competitive Landscape
Challenges and Opportunities
Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
MARKET INTRODUCTION
Definition
Scope of the study
Research Objective
Assumption
Limitations
RESEARCH METHODOLOGY
Overview
Data Mining
Secondary Research
Primary Research
Primary Interviews and Information Gathering Process
Breakdown of Primary Respondents
Forecasting Model
Market Size Estimation
Bottom-Up Approach
Top-Down Approach
Data Triangulation
Validation
3 SECTION III: QUALITATIVE ANALYSIS
MARKET DYNAMICS
Overview
Drivers
Restraints
Opportunities
MARKET FACTOR ANALYSIS
Value chain Analysis
Porter's Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of New Entrants
Threat of Substitutes
Intensity of Rivalry
COVID-19 Impact Analysis
Market Impact Analysis
Regional Impact
Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
Healthcare
Market Segmentation
Japan Healthcare By Application (USD Billion, 2025-2035)Adverse Event Reporting
Risk Management
Data Mining
Pharmacovigilance System Master File
Signal Detection
Healthcare By End Use (USD Billion, 2025-2035)Pharmaceutical Companies
Contract Research Organizations
Regulatory Authorities
Biotechnology Companies
Healthcare By Type (USD Billion, 2025-2035)Clinical Trials
Post-Marketing Surveillance
Pre-Marketing Surveillance
Risk Assessment
Healthcare
By Service Type (USD Billion, 2025-2035)Consulting Services
Data Management Services
Safety Database Services
Medical Writing Services SECTION V: COMPETITIVE ANALYSIS
Competitive Landscape
Overview
Competitive Analysis
Market share Analysis
Major Growth Strategy in the pharmacovigilance market
Competitive Benchmarking
Leading Players in Terms of Number of Developments in the pharmacovigilance market
Key developments and growth strategies
New Product Launch/Service Deployment
Merger & Acquisitions
Joint Ventures
Major Players Financial Matrix
Sales and Operating Income
Major Players R&D Expenditure. 2023
Company Profiles
Takeda Pharmaceutical Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Astellas Pharma Inc.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Daiichi Sanky
Company Limited
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Mitsubishi Tanabe Pharma Corporation
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Otsuka Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Eisai Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Chugai Pharmaceutical Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Kyowa Kirin Co., Ltd.
Financial Overview
Products Offered
Key Developments
SWOT Analysis
Key Strategies
Appendix
References
Related Reports

COMPANIES MENTIONED
Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd.

ページTOPに戻る

List of Tables/Graphs

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY SERVICE TYPE
FIGURE 3 JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY DEPLOYMENT MODE
FIGURE 4 JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY SOURCE
FIGURE 5 JAPAN PHARMACOVIGILANCE MARKET ANALYSIS BY END USER
FIGURE 6 KEY BUYING CRITERIA OF PHARMACOVIGILANCE MARKET
FIGURE 7 RESEARCH PROCESS OF MRFR
FIGURE 8 DRO ANALYSIS OF JAPAN PHARMACOVIGILANCE MARKET
FIGURE 9 DRIVERS IMPACT ANALYSIS: JAPAN PHARMACOVIGILANCE MARKET
FIGURE 10 RESTRAINTS IMPACT ANALYSIS: JAPAN PHARMACOVIGILANCE MARKET
FIGURE 11 SUPPLY / VALUE CHAIN: JAPAN PHARMACOVIGILANCE MARKET
FIGURE 12 JAPAN PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2024 (% SHARE)
FIGURE 13 JAPAN PHARMACOVIGILANCE MARKET, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
FIGURE 14 JAPAN PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2024 (% SHARE)
FIGURE 15 JAPAN PHARMACOVIGILANCE MARKET, BY DEPLOYMENT MODE, 2024 TO 2035 (USD Million)
FIGURE 16 JAPAN PHARMACOVIGILANCE MARKET, BY SOURCE, 2024 (% SHARE)
FIGURE 17 JAPAN PHARMACOVIGILANCE MARKET, BY SOURCE, 2024 TO 2035 (USD Million)
FIGURE 18 JAPAN PHARMACOVIGILANCE MARKET, BY END USER, 2024 (% SHARE)
FIGURE 19 JAPAN PHARMACOVIGILANCE MARKET, BY END USER, 2024 TO 2035 (USD Million)
FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS

LIST OF TABLES
LIST OF ASSUMPTIONS
Japan PHARMACOVIGILANCE MARKET SIZE ESTIMATES; FORECAST
TABLE 1 BY SERVICE TYPE, 2026-2035 (USD Million)
TABLE 2 BY SERVICE TYPE, 2026-2035 (USD Million)
TABLE 3 BY DEPLOYMENT MODE, 2026-2035 (USD Million)
TABLE 4 BY DEPLOYMENT MODE, 2026-2035 (USD Million)
TABLE 5 BY SOURCE, 2026-2035 (USD Million)
TABLE 6 BY SOURCE, 2026-2035 (USD Million)
TABLE 7 BY END USER, 2026-2035 (USD Million)
TABLE 8 BY END USER, 2026-2035 (USD Million)
PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
ACQUISITION/PARTNERSHIP